Digestive Disease Interventions

LinksSchließen

Referenz

Heinemann V, von Weikersthal LF, Decker T. et al.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Lancet Oncol 2014;
15 (10) 1065-1075

Bibliographische Angaben herunterladen

Aufrufen in: